Diagnostic ultrasound ( PDFDrive )

CHAPTER 10 The Prostate and Transrectal Ultrasound 413
41. Pontari MA. Etiologic theories of chronic prostatitis/chronic pelvic pain
syndrome. Curr Urol Rep. 2007;8(4):307-312.
42. Galosi AB, Montironi R, Fabiani A, et al. Cystic lesions of the prostate
gland: an ultrasound classiication with pathological correlation. J Urol.
2009;181(2):647-657.
43. Nghiem HT, Kellman GM, Sandberg SA, Craig BM. Cystic lesions of the
prostate. Radiographics. 1990;10(4):635-650.
44. Curran S, Akin O, Agildere AM, et al. Endorectal MRI of prostatic and
periprostatic cystic lesions and their mimics. AJR Am J Roentgenol.
2007;188(5):1373-1379.
45. Kim B, Kawashima A, Ryu JA, et al. Imaging of the seminal vesicle and vas
deferens. Radiographics. 2009;29(4):1105-1121.
46. Reddy MN, Verma S. Lesions of the seminal vesicles and their MRI
characteristics. J Clin Imaging Sci. 2014;4:61.
47. Patel B, Gujral S, Jeferson K, et al. Seminal vesicle cysts and associated
anomalies. BJU Int. 2002;90(3):265-271.
48. Jarow J, Sigman M, Kolettis PN, et al. he Optimal Evaluation of the Infertile
Male: Best Practice Statement Reviewed and validity conirmed 2011. Cited
24 April 2016. Available from: https://www.auanet.org/education/guidelines/
male-infertility-d.cfm.
49. Jungwirth A, Giwercman A, Tournaye H, et al. European Association of
Urology guidelines on male infertility: the 2012 update. Eur Urol.
2012;62(2):324-332.
50. Smith JF, Walsh TJ, Turek PJ. Ejaculatory duct obstruction. Urol Clin North
Am. 2008;35(2):221-227, viii.
51. Fedder J, Cruger D, Oestergaard B, Petersen GB. Etiology of azoospermia
in 100 consecutive nonvasectomized men. Fertil Steril. 2004;82(5):
1463-1465.
52. Ammar T, Sidhu PS, Wilkins CJ. Male infertility: the role of imaging in
diagnosis and management. Br J Radiol. 2012;85(Spec No. 1):S59-S68.
53. Jhaveri KS, Mazrani W, Chawla TP, et al. he role of cross-sectional imaging
in male infertility: a pictorial review. Can Assoc Radiol J. 2010;61(3):
144-155.
54. Akhter W, Khan F, Chinegwundoh F. Should every patient with hematospermia
be investigated? A critical review. Cent European J Urol.
2013;66(1):79-82.
55. Aslam MI, Cheetham P, Miller MA. A management algorithm for hematospermia.
Nat Rev Urol. 2009;6(7):398-402.
56. Prando A. Endorectal magnetic resonance imaging in persistent hematospermia.
Int Braz J Urol. 2008;34(2):171-179.
57. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.
2016;66(1):7-30.
58. Tabayoyong W, Abouassaly R. Prostate cancer screening and the associated
controversy. Surg Clin North Am. 2015;95(5):1023-1039.
59. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade
grouping: data based on the modiied Gleason scoring system. BJU Int.
2013;111(5):753-760.
60. Carlsson S, Leapman M, Carroll P, et al. Who and when should we screen
for prostate cancer? Interviews with key opinion leaders. BMC Med.
2015;13:288.
61. Cotter K, Konety B, Ordonez MA. Contemporary management of prostate
cancer. F1000Res. 2016;5.
62. Agency for Healthcare Research and Quality (AHRQ). herapies for clinically
localized prostate cancer. Comparative efectiveness review summary guides
for clinicians. AHRQ Comparative Efectiveness Reviews. Rockville, MD:
Agency for Healthcare Research and Quality; 2016.
63. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative
efectiveness and harms of treatments for clinically localized prostate cancer.
Ann Intern Med. 2008;148(6):435-448.
64. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative
management of clinically localized prostate cancer. JAMA. 2005;293(17):
2095-2101.
65. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on
autopsy: cross-sectional study on unscreened Caucasian and Asian men.
J Natl Cancer Inst. 2013;105(14):1050-1058.
66. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with
outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):
1250-1261.
67. Nam RK, Jewett MA, Krahn MD. Prostate cancer: 2. Natural history. CMAJ.
1998;159(6):685-691.
68. Catalona WJ, Smith DS, Ratlif TL, et al. Measurement of prostate-speciic
antigen in serum as a screening test for prostate cancer. N Engl J Med.
1991;324(17):1156-1161.
69. Stephenson AJ, Klein E. Epidemiology, etiology, and prevention of prostate
cancer. 11th ed. Philadelphia, PA: Elsevier; 2016.
70. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk
factors. Cancer. 2004;101(10 Suppl.):2371-2490.
71. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168(3):
906-913.
72. Chang JM, Lee HJ, Lee SE, et al. Pictorial review: unusual tumours involving
the prostate: radiological-pathological indings. Br J Radiol. 2008;81(971):
907-915.
73. Eggener SE, Badani K, Barocas DA, et al. Gleason 6 prostate cancer: translating
biology into population health. J Urol. 2015;194(3):626-634.
74. Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer.
Oncology (Williston Park). 2014;28(2):135-142.
75. Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol
(Dordr). 2016;39(2):97-106.
76. Morgan T, Palapattu G, Wei J. Screening for Prostate cancer—beyond total
PSA, utilization of novel biomarkers. Curr Urol Rep. 2015;16(9):63.
77. Leapman MS, Nguyen HG, Cooperberg MR. Clinical utility of biomarkers
in localized prostate cancer. Curr Oncol Rep. 2016;18(5):30.
78. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free
prostate-speciic antigen to enhance diferentiation of prostate cancer from
benign prostatic disease: a prospective multicenter clinical trial. JAMA.
1998;279(19):1542-1547.
79. Elliott CS, Shinghal R, Presti Jr JC. he performance of prostate speciic
antigen, prostate speciic antigen density and transition zone density in the
era of extended biopsy schemes. J Urol. 2008;179(5):1756-1761.
80. Morash C. PSA density: he comeback kid? Can Urol Assoc J. 2012;6(1):
51-52.
81. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostatespeciic
antigen levels in men with and without prostate disease. JAMA.
1992;267(16):2215-2220.
82. Iremashvili V, Kava BR, Manoharan M, et al. Is it time to revisit the role
of prostate-speciic antigen kinetics in active surveillance for prostate cancer?
Urology. 2016;95:139-144.
83. Eggener S. Prostate cancer screening biomarkers: an emerging embarrassment
of ‘riches’? Eur Urol. 2016;70(1):54-55.
84. Stephan C, Ralla B, Jung K. Prostate-speciic antigen and other serum and
urine markers in prostate cancer. Biochim Biophys Acta. 2014;1846(1):
99-112.
85. Filella X, Foj L. Emerging biomarkers in the detection and prognosis of
prostate cancer. Clin Chem Lab Med. 2015;53(7):963-973.
86. Foley RW, Maweni RM, Gorman L, et al. he ERSPC risk calculators signiicantly
outperform the PCPT 2.0 in the prediction of prostate cancer; a
multi-institutional study. BJU Int. 2016 Feb 2. [Epub ahead of print].
87. Trottier G, Roobol MJ, Lawrentschuk N, et al. Comparison of risk calculators
from the Prostate Cancer Prevention Trial and the European Randomized
Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
BJU Int. 2011;108(8 Pt 2):E237-E244.
88. Shieh Y, Eklund M, Sawaya GF, et al. Population-based screening for cancer:
hope and hype. Nat Rev Clin Oncol. 2016;13(9):550-565.
89. Heintz E, Hultcrantz M, Mejare I, et al. Limited evidence for the use of
imaging to detect prostate cancer: a systematic review. Eur J Radiol.
2014;83(9):1601-1606.
90. Bjurlin MA, Rosenkrantz AB, Beltran LS, et al. Imaging and evaluation of
patients with high-risk prostate cancer. Nat Rev Urol. 2015;12(11):617-628.
91. Sarkar S, Das S. A review of imaging methods for prostate cancer detection.
Biomed Eng Comput Biol. 2016;7(Suppl. 1):1-15.
92. Wibmer AG, Burger IA, Sala E, et al. Molecular imaging of prostate cancer.
Radiographics. 2016;36(1):142-159.
93. Babaian RJ, Mettlin C, Kane R, et al. he relationship of prostate-speciic
antigen to digital rectal examination and transrectal ultrasonography. Findings
of the American Cancer Society National Prostate Cancer Detection Project.
Cancer. 1992;69(5):1195-1200.